Entrada Therapeutics Inc (TRDA)
18.80
+0.75
(+4.16%)
USD |
NASDAQ |
Nov 22, 12:11
Entrada Therapeutics Total Liabilities (Quarterly): 132.14M for Sept. 30, 2024
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 132.14M |
| June 30, 2024 | 152.04M |
| March 31, 2024 | 241.48M |
| December 31, 2023 | 226.83M |
| September 30, 2023 | 238.37M |
| June 30, 2023 | 287.08M |
| March 31, 2023 | 245.96M |
| December 31, 2022 | 39.50M |
| Date | Value |
|---|---|
| September 30, 2022 | 41.24M |
| June 30, 2022 | 39.88M |
| March 31, 2022 | 39.31M |
| December 31, 2021 | 7.115M |
| September 30, 2021 | 204.99M |
| June 30, 2021 | 202.53M |
| December 31, 2020 | 85.02M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
7.115M
Minimum
Dec 2021
287.08M
Maximum
Jun 2023
145.56M
Average
152.04M
Median
Jun 2024
Total Liabilities (Quarterly) Benchmarks
| Catalyst Pharmaceuticals Inc | 111.07M |
| Vertex Pharmaceuticals Inc | 6.609B |
| Assembly Biosciences Inc | 74.26M |
| Sarepta Therapeutics Inc | 2.379B |
| Regenxbio Inc | 217.70M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 554.59M |
| Shareholders Equity (Quarterly) | 422.45M |
| Current Ratio | 6.591 |